Comparison of efficacy of Ketorolac %0.4 and Dexamethasone %0.1 in inflamed Pterygium and Pinguecula

Year 2023, Volume: 14 Issue: 49, 126 - 131, 31.08.2023

Kaan Çakmak Safak Korkmaz Funda Yılmaz

https://doi.org/10.17944/interdiscip.1352006

Abstract

Objective: This study investigated the effect of the ketorolac %0.4 and dexamethasone %0.1 on suppressing symptoms in inflamed pterygium and pinguecula.

Methods: 50 patients were included in the study. The patients were divided into two groups, each consisting of 25 patients. Ketorolac %0.4 eye drops were dropped in group 1, and dexamethasone %0.1 eye drops were started in group 2. Groups were compared 3,7,14,30,45. days in terms of total signs and symptoms.

Results: After 14 days of drug administration group 1, scores were reduced %85 for total signs (2.52+1.16, p=0.001), %86 for total symptoms (4.10+2.61, p=0.001) and total scores showed a significant reduction of %86 (6.62+2.91, p=0.001) for the score. After 14 days of drug administration in group 2, scores were reduced %85 for total signs (2.70+1.46, p=0.001), %86 for total symptoms (4.25+2.36, p=0.001), and total scores showed a significant reduction of %86 (7.10+2.99, p=0.001) for the score. The scores for each sign and symptom decreased during the study. However, the statistical evaluation of each sign and symptom was similar in groups 1 and 2. There was no difference between groups 1 and 2 for total signs, total symptoms, and total score on days 3,7 and 14. No significant difference was found between groups 1 and 2 for total signs, total symptoms, and total score on days 14,30 and 45 (p>0.05).

Conclusion: Current study revealed that topical ketorolac %0.4 solutions are as effective as dexamethasone in treating inflammatory pterygium and pinguecula. We suggest that it can be used alone to treat this disease. We need more studies to support our work.

Keywords

Pterygium, Pinguecula, Ketorolac, Dexamethasone

References

• Corn and G. Pterygium. Clinical course and treatment. Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique. 1989;66(3-4):31-108. Eng-lish, French.
• Duke-ElderS.Systemofophthalmology:diseasesoftheouter eye, Vol 8, Part 1. London: Henry Kimpton, 1965:570–583.
• Austin P, Jakobiec FA, Iwamoto T. Elastodysplasia and elastodystrophy as the pathologic bases of ocular pterygia and pinguecula. Oph-thalmology. 1983 Jan;90(1):96-109. https://doi.org/10.1016/s0161-6420(83)34594-2.
• Detels R, Dhir SP. Pterygium: a geographical study. Arch Ophthalmol. 1967 Oct;78(4):485-91. https://doi.org/10.1001/archopht.1967.00980030487014.
• King JH Jr. The pterygium; brief review and evaluation of specific methods of treatment. AMA Arch Ophthalmol. 1950 Dec;44(6):854-69.
• Pinkerton OD, Hokama Y, Shigemura LA. Immunologic basis for the pathogenesis of pterygium. Am J Ophthalmol. 1984 Aug 15;98(2):225-8 https://doi.org/10.1016/0002-9394(87)90358-8.
• Wong WW. A hypothesis on the pathogenesis of pterygiums. Ann Ophthalmol. 1978 Mar;10(3):303-8.
• Kraff MC, Sanders DR, Jampol LM, Peyman GA, Lieberman HL. Prophylaxis of pseudophakic cystoid macular edema with topical indo-methacin. Ophthalmology. 1982 Aug;89(8):885-90. https://doi.org/10.1016/s0161-6420(82)34710-7.
• Turkyilmaz K, Oner V, Sevim MS, Kurt A, Sekeryapan B, Durmus M: Effect of pterygium surgery on tear osmolarity. J Ophthalmol 2013;2013:863498.
• Jaros P. A., DeLuise V. P. Pingueculae and pterygia. Survey of Ophthalmology. 1988;33(1):41–49. https://doi.org/10.1016/0039-6257()90071-9.
• Fotouhi A., Hashemi H., Khabazkhoob M., Mohammad K. Prevalence and risk factors of pterygium and pinguecula: the Tehran eye study. Eye. 2009;23(5):1125–1129. https://doi.org/10.1038/eye.2008.200.
• Li Z. Y., Wallace R. N., Streeten B. W., Kuntz B. L., Dark A. J. Elastic fiber components and protease inhibitors in pinguecula. Investigative Ophthalmology and Visual Science. 1991;32(5):1573–1585.
• Pham T. Q., Wang J. J., Rochtchina E., Mitchell P. Pterygium/pinguecula and the five-year incidence of age-related maculopathy. Ameri-can Journal of Ophthalmology. 2005;139(3):536–537. https://doi.org/10.1016/j.ajo.2004.08.070.
• Jobling AI, Augusteyn RC. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom. 2002 Mar;85(2):61-75. https://doi.org/10.1111/j.1444-0938.2002.tb03011.x.
• Keates RH, McGowan KA. The effect of topical indomethacin ophthalmic solution in maintaining mydriasis during cataract surgery. Ann Ophthalmol. 1984 Dec;16(12):1116-21.
• Kraff MC, Sanders DR, McGuigan L, Raanan MG. Inhibition of blood-aqueous humor barrier breakdown with diclofenac. A fluoropho-tometric study. Arch Ophthalmol. 1990 Mar;108(3):380-3. https://doi.org/10.1001/archopht.1990.01070050078035.
• Frucht-Pery J, Levinger S, Zauberman H. The effect of topical administration of indomethacin on corneal scars and edema symptoms. Am J Ophthalmol. 1991 Aug 15;112(2):186-90. https://doi.org/10.1016/s0002-9394(14)76699-1.
• Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol. 1992 Jan-Feb;36(4):259-84. https://doi.org/10.1016/0039-6257(92)90095-b.
• Frucht-Pery J, Solomon A, Siganos CS, Shvartzenberg T, Richard C, Trinquand C. Treatment of inflamed pterygium and pinguecula with topical indomethacin 0.1% solution. Cornea. 1997 Jan;16(1):42-7.
• Herschel MK, McDonald MB, Ahmed S, Klyce SD, Varnell RJ, Thompson HW. Voltaren for treatment of discomfort after excimer ablation. ARVO abstracts. Invest Ophthalmol Vis Sci 34(4,suppl);1993:893.
• Szerenyi K, Sorken K, Garbus JJ, Lee M, McDonnell PJ. Decrease in normal human corneal sensitivity with topical diclofenac sodium. Am J Ophthalmol. 1994 Sep 15;118(3):312-5. https://doi.org/10.1016/s0002-9394(14)72954-x.
• Notivol R, Martínez M, Bergamini MV. Treatment of chronic nonbacterial conjunctivitis with a cyclo-oxygenase inhibitor or a corticoster-oid. Pranoprofen Study Group. Am J Ophthalmol. 1994 May 15;117(5):651-6. https://doi.org/10.1016/s0002-9394(14)70073-x.
• Flach AJ, Graham J, Kruger LP, Stegman RC, Tanenbaum L. Quantitative assessment of postsurgical breakdown of the blood-aqueous barrier following administration of 0.5% ketorolac tromethamine solution. A double-masked, paired comparison with vehicle-placebo solution study. Arch Ophthalmol. 1988 Mar;106(3):344-7. https://doi.org/10.1001/archopht.1988.01060130370024.
• Teräsvirta M. Topical indomethacin in extracapsular cataract surgery. A photographic study. Acta Ophthalmol (Copenh). 1989 Jun;67(3):339-41. https://doi.org/10.1111/j.1755-3768.1989.tb01884.x.
• Sanders DR, Kraff M. Steroidal and non-steroidal anti-inflammatory agents. Effect on postsurgical inflammation and blood-aqueous humor barrier breakdown. Arch Ophthalmol. 1984 Oct;102(10):1453-6. https://doi.org/10.1001/archopht.1984.01040031173012.
• Sabiston D, Tessler H, Sumers K, Osterle C, Cheetham JK, Guzman E, DeGryse R. Reduction of inflammation following cataract surgery by the non-steroidal anti-inflammatory drug, flurbiprofen. Ophthalmic Surg. 1987 Dec;18(12):873-7.
• Weinreb RN, Robin AL, Baerveldt G, Drake MV, Blumenthal M, Wilensky J. Flurbiprofen pretreatment in argon laser trabeculoplasty for primary open-angle glaucoma. Arch Ophthalmol. 1984 Nov;102(11):1629-32. https://doi.org/10.1001/archopht.1984.01040031319016.
• Flach AJ, Kraff MC, Sanders DR, Tanenbaum L. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexame-thasone sodium phosphate solution on postsurgical blood-aqueous barrier. Arch Ophthalmol. 1988 Apr;106(4):480-3. https://doi.org/10.1001/archopht.1988.01060130526028.
• Flach AJ, Jaffe NS, Akers WA. The effect of ketorolac tromethamine in reducing postoperative inflammation: double-mask parallel com-parison with dexamethasone. Ann Ophthalmol. 1989 Nov;21(11):407-11.
• Frucht-Pery J, Siganos CS, Solomon A, Shvartzenberg T, Richard C, Trinquand C. Topical indomethacin solution versus dexamethasone solution for treatment of inflamed pterygium and pinguecula: a prospective randomized clinical study. Am J Ophthalmol. 1999 Feb;127(2):148-52. https://doi.org/10.1016/s0002-9394(98)00327-4.
• Carlock BH, Bienstock CA, Rogosnitzky M. Pterygium: nonsurgical treatment using topical dipyridamole - a case report. Case Rep Oph-thalmol. 2014 Mar 25;5(1):98-103. https://doi.org/10.1159/000362113